237 related articles for article (PubMed ID: 28267637)
1. Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis.
Garcia-Vidal C; Sanchez-Rodriguez I; Simonetti AF; Burgos J; Viasus D; Martin MT; Falco V; Carratalà J
Clin Microbiol Infect; 2017 Sep; 23(9):653-658. PubMed ID: 28267637
[TBL] [Abstract][Full Text] [Related]
2. [Treatment for Legionnaires' disease. Macrolides or quinolones?].
Falcó V; Molina I; Juste C; Crespo M; Almirante B; Pigrau C; Ferrer A; Bravo C; Palomar M; Pahissa A
Enferm Infecc Microbiol Clin; 2006; 24(6):360-4. PubMed ID: 16792936
[TBL] [Abstract][Full Text] [Related]
3. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Griffin AT; Peyrani P; Wiemken T; Arnold F
Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
Mykietiuk A; Carratalà J; Fernández-Sabé N; Dorca J; Verdaguer R; Manresa F; Gudiol F
Clin Infect Dis; 2005 Mar; 40(6):794-9. PubMed ID: 15736010
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides.
Blázquez Garrido RM; Espinosa Parra FJ; Alemany Francés L; Ramos Guevara RM; Sánchez-Nieto JM; Segovia Hernández M; Serrano Martínez JA; Huerta FH
Clin Infect Dis; 2005 Mar; 40(6):800-6. PubMed ID: 15736011
[TBL] [Abstract][Full Text] [Related]
6. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
[TBL] [Abstract][Full Text] [Related]
7. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization.
Plouffe JF; Breiman RF; Fields BS; Herbert M; Inverso J; Knirsch C; Kolokathis A; Marrie TJ; Nicolle L; Schwartz DB
Clin Infect Dis; 2003 Dec; 37(11):1475-80. PubMed ID: 14614670
[TBL] [Abstract][Full Text] [Related]
8. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia.
Grau S; Antonio JM; Ribes E; Salvadó M; Garcés JM; Garau J
Int J Antimicrob Agents; 2006 Sep; 28(3):249-52. PubMed ID: 16870401
[TBL] [Abstract][Full Text] [Related]
9. Severe Legionnaires' disease successfully treated with levofloxacin and azithromycin.
Pedro-Botet ML; García-Cruz A; Tural C; Mateu L; Sopena N; Roure S; Rey-Joly C; Sabria M
J Chemother; 2006 Oct; 18(5):559-61. PubMed ID: 17127236
[No Abstract] [Full Text] [Related]
10. Treatment strategies for Legionella infection.
Pedro-Botet ML; Yu VL
Expert Opin Pharmacother; 2009 May; 10(7):1109-21. PubMed ID: 19405787
[TBL] [Abstract][Full Text] [Related]
11. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H
J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381
[TBL] [Abstract][Full Text] [Related]
12. Current clinical management of Legionnaires' disease.
Garcia-Vidal C; Carratalà J
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):995-1004. PubMed ID: 17181416
[TBL] [Abstract][Full Text] [Related]
13. Treatment of legionnaires' disease.
Klein NC; Cunha BA
Semin Respir Infect; 1998 Jun; 13(2):140-6. PubMed ID: 9643392
[TBL] [Abstract][Full Text] [Related]
14. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
[TBL] [Abstract][Full Text] [Related]
15. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study.
Kuzman I; Soldo I; Schönwald S; Culig J
Scand J Infect Dis; 1995; 27(5):503-5. PubMed ID: 8588143
[TBL] [Abstract][Full Text] [Related]
16. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
[TBL] [Abstract][Full Text] [Related]
17. The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with Legionella pneumonia.
Gershengorn HB; Keene A; Dzierba AL; Wunsch H
Clin Infect Dis; 2015 Jun; 60(11):e66-79. PubMed ID: 25722195
[TBL] [Abstract][Full Text] [Related]
18. Is a 5 day course of azithromycin enough for infections caused by Legionella pneumophila?
Matute AJ; Schurink CA; Hoepelman IM
J Antimicrob Chemother; 2000 Jun; 45(6):930-1. PubMed ID: 10837459
[No Abstract] [Full Text] [Related]
19. Legionellosis.
Pedro-Botet ML; Sabrià M
Semin Respir Crit Care Med; 2005 Dec; 26(6):625-34. PubMed ID: 16388431
[TBL] [Abstract][Full Text] [Related]
20. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
Sato T; Tateda K; Kimura S; Ishii Y; Yamaguchi K
Antimicrob Agents Chemother; 2011 Apr; 55(4):1594-7. PubMed ID: 21220530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
